 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...510511512513514515516517518519520521522» |
- | New P4 trial: Treatment of Peripheral T-cell Lymphoma (clinicaltrials.gov) - Aug 12, 2012
P4, N=100, Recruiting, Sponsor: Mingzhi Zhang
- ||| dasatinib / Generic mfg.
Enrollment closed: Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. (clinicaltrials.gov) - Aug 12, 2012
P2, N=115, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting
- ||| Avastin (bevacizumab) / Roche
Enrollment closed, Combination therapy: A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma (clinicaltrials.gov) - Aug 7, 2012
P2, N=95, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | New P4 trial, Metastases: An Open-label, Multi-center Phase ? Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel (clinicaltrials.gov) - Aug 6, 2012
P4, N=95, Recruiting, Sponsor: Yonsei University
- cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
New P2 trial, Surgery: A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers (clinicaltrials.gov) - Aug 6, 2012
P2, N=20, Recruiting, Sponsor: Columbia University
- Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Enrollment closed: Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma (clinicaltrials.gov) - Aug 6, 2012
P2, N=39, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Biomarker, New P3 trial: GAINED: GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Aug 5, 2012
P3, N=670, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
- Rituxan (rituximab) / Roche
New P2 trial: A trial to investigate treatment with EPOCH-R in patients with Burkitt lymphoma, by adapting the dose to the risk classification of the disease. (EUDRACT) - Aug 5, 2012
P2, N=22, Ongoing, Sponsor: VU University Medical Center
- Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
New P2 trial, Surgery: Laboratory Treated T Cells After Chemotherapy in Treating Patients With HER2-Negative Stage II-III Breast Cancer That Can Be Removed By Surgery (clinicaltrials.gov) - Aug 5, 2012
P2, N=48, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
- mesna / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment closed: Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-?) Release (clinicaltrials.gov) - Aug 5, 2012
P2, N=40, Active, not recruiting, Sponsor: John Haslip
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Torisel (temsirolimus) / Pfizer
Trial initiation date: Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (clinicaltrials.gov) - Aug 2, 2012
P3, N=216, Recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Initiation date: Nov 2008 --> Sep 2009
- ||||| Enrollment change, Surgery: AREN0534: Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor (clinicaltrials.gov) - Aug 2, 2012
P3, N=260, Recruiting, Sponsor: Children's Oncology Group
Initiation date: Nov 2008 --> Sep 2009 N=150 --> 260
- |||| Halaven (eribulin mesylate) / Eisai
Enrollment open: Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 (clinicaltrials.gov) - Aug 2, 2012
P2, N=162, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=150 --> 260 Not yet recruiting --> Recruiting
- ||||||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial completion: An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS) (clinicaltrials.gov) - Jul 25, 2012
P3, N=80, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||||||||| Rituxan (rituximab) / Roche, Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
New P3 trial, Combination therapy: A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Jul 23, 2012
P3, N=600, Recruiting, Sponsor: Hoffmann-La Roche
- | Enrollment change: IBCSG-15-95: High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer (clinicaltrials.gov) - Jul 19, 2012
P3, N=344, Completed, Sponsor: International Breast Cancer Study Group
Recruiting --> Completed N=210 --> 344
- | Trial completion: IBCSG-15-95: High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer (clinicaltrials.gov) - Jul 19, 2012
P3, N=344, Completed, Sponsor: International Breast Cancer Study Group
N=210 --> 344 Active, not recruiting --> Completed
- | Trial completion: EU-93015: Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer (clinicaltrials.gov) - Jul 19, 2012
P3, N=452, Completed, Sponsor: International Breast Cancer Study Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || New P3 trial, Metastases: High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer (clinicaltrials.gov) - Jul 18, 2012
P3, N=86, Recruiting, Sponsor: The Netherlands Cancer Institute
- || Oncaspar liquid (pegaspargase) / Servier
Enrollment closed: AALL08P1: Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011) (clinicaltrials.gov) - Jul 18, 2012
P=N/A, N=165, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Suspended --> Active, not recruiting
- Zinapar (darinaparsin) / Solasia, Meiji Seika, Nippon Kayaku
Enrollment change, Combination therapy: Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma (clinicaltrials.gov) - Jul 17, 2012
P1, N=0, Withdrawn, Sponsor: Ziopharm
Suspended --> Active, not recruiting N=15 --> 0
- ||||| leucovorin calcium / Generic mfg., thioguanine / Generic mfg.
Enrollment closed: AALL0232: Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 17, 2012
P3, N=3154, Active, not recruiting, Sponsor: Children's Oncology Group
N=15 --> 0 Suspended --> Active, not recruiting
- ||| doxorubicin hydrochloride / Generic mfg.
Enrollment change, Metastases: PICASSO: A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma (clinicaltrials.gov) - Jul 16, 2012
P2, N=67, Active, not recruiting, Sponsor: Ziopharm
Suspended --> Active, not recruiting N=100 --> 67
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial withdrawal, Combination therapy, Metastases: Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 10, 2012
P1, N=0, Withdrawn, Sponsor: The University of Texas Health Science Center at San Antonio
N=100 --> 67 Not yet recruiting --> Withdrawn
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Enrollment change, Combination therapy, Metastases: Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 10, 2012
P1, N=0, Withdrawn, Sponsor: The University of Texas Health Science Center at San Antonio
Not yet recruiting --> Withdrawn N=70 --> 0
- New P2 trial: Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer (clinicaltrials.gov) - Jul 10, 2012
P2, N=0, Withdrawn, Sponsor: University of Southern California
- | doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg., gemcitabine / Generic mfg.
Enrollment open, Surgery: GOG study : Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery (clinicaltrials.gov) - Jul 10, 2012
P3, N=216, Recruiting, Sponsor: Gynecologic Oncology Group
N=70 --> 0 Not yet recruiting --> Recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Herceptin (trastuzumab) / Roche
Trial completion, Surgery: Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery (clinicaltrials.gov) - Jul 10, 2012
P2, N=60, Completed, Sponsor: University of Washington
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| Pixuvri (pixantrone) / Servier, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin (clinicaltrials.gov) - Jul 10, 2012
P2, N=280, Completed, Sponsor: Cell Therapeutics
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Surgery: SWOG-EORTC-62933: Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 9, 2012
P3, N=340, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Decadron (dexamethasone) / Merck (MSD)
New P4 trial, CINV: A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC) (clinicaltrials.gov) - Jul 8, 2012
P4, N=492, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- Enrollment change: PEPI: Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma (clinicaltrials.gov) - Jul 2, 2012
P2, N=13, Active, not recruiting, Sponsor: Baylor College of Medicine
Active, not recruiting --> Completed N=30 --> 13
- ABT-751 / AbbVie, Eisai
Enrollment change: ABT-751 With Chemotherapy for Relapsed Pediatric ALL (clinicaltrials.gov) - Jun 28, 2012
P1/2, N=9, Terminated, Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
N=30 --> 13 N=35 --> 9
- dexamethasone / Generic mfg., lenalidomide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion: Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Jun 26, 2012
P2, N=146, Completed, Sponsor: Wuerzburg University Hospital
N=35 --> 9 Recruiting --> Completed
- ||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia (clinicaltrials.gov) - Jun 18, 2012
P2/3, N=640, Recruiting, Sponsor: Children's Oncology Group
Recruiting --> Completed Initiation date: Jan 2012 --> Jun 2012
- |||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia (clinicaltrials.gov) - Jun 18, 2012
P2/3, N=640, Recruiting, Sponsor: Children's Oncology Group
Initiation date: Jan 2012 --> Jun 2012 Not yet recruiting --> Recruiting
- || New P3 trial: NEST: Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer (clinicaltrials.gov) - Jun 17, 2012
P3, N=290, Recruiting, Sponsor: Asan Medical Center
- Rituxan (rituximab) / Roche
New P1/2 trial, Combination therapy: VALFRID: Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Jun 17, 2012
P1/2, N=50, Recruiting, Sponsor: Lund University Hospital
- || brivanib alaninate (BMS-582664) / ZAI Lab
Enrollment closed, Combination therapy, Metastases: Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers (clinicaltrials.gov) - Jun 17, 2012
P1, N=189, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Strontium89 (strontium chloride Sr-89 injection, USP) / Q BioMed
Trial initiation date: Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Jun 14, 2012
P3, N=480, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Initiation date: Oct 2001 --> Apr 2002
- Avastin (bevacizumab) / Roche
Enrollment change, Metastases: Phase II Study of Doxorubicin and Avastin (clinicaltrials.gov) - Jun 10, 2012
P2, N=4, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Initiation date: Oct 2001 --> Apr 2002 N=68 --> 4
- Neocarzinostatin (zinostatin) / Astellas
Trial withdrawal: Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma (clinicaltrials.gov) - Jun 6, 2012
P3, N=0, Withdrawn, Sponsor: Albert Koong
N=68 --> 4 Recruiting --> Withdrawn
- Neocarzinostatin (zinostatin) / Astellas
Enrollment change: Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma (clinicaltrials.gov) - Jun 6, 2012
P3, N=0, Withdrawn, Sponsor: Albert Koong
Recruiting --> Withdrawn N=120 --> 0
- sorafenib / Generic mfg.
Trial initiation date, Metastases: Sorafenib VS TACE in HCC Patients With Portal Vein Invasion (clinicaltrials.gov) - Jun 5, 2012
P2, N=40, Recruiting, Sponsor: Seoul National University Hospital
N=120 --> 0 Initiation date: Nov 2011 --> Jun 2012
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Mustargen (mechlorethamine) / Recordati
Enrollment closed: Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma (clinicaltrials.gov) - Jun 5, 2012
P2, N=82, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Initiation date: Nov 2011 --> Jun 2012 Recruiting --> Active, not recruiting
- ||||||| Neugranin (balugrastim biosimilar) / Teva
Trial completion, Head-to-Head: NEUGR-003: Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel (clinicaltrials.gov) - Jun 3, 2012
P3, N=381, Completed, Sponsor: Teva Pharmaceutical Industries
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Enrollment open: ASTER 70s: Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment (clinicaltrials.gov) - May 28, 2012
P3, N=2000, Recruiting, Sponsor: UNICANCER
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- sorafenib / Generic mfg.
Trial completion: Combination of Transcatheter Arterial Chemoembolization (TACE) and Sorafenib for Patients With Unresectable Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - May 28, 2012
P2, N=50, Completed, Sponsor: National Cancer Center, Korea
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| Xalkori (crizotinib) / Pfizer
New P1 trial, Combination therapy: Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (clinicaltrials.gov) - May 24, 2012
P1, N=58, Recruiting, Sponsor: Children's Oncology Group
- | RG7112 / Roche
New P1 trial, Combination therapy: A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - May 23, 2012
P1, N=23, Completed, Sponsor: Hoffmann-La Roche